Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Clinical trial NCT04609176 · UNKNOWN
Trial details
- NCT number
- NCT04609176
- Sponsor
- Peking University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-18
- Primary completion
- 2023-12-31
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.